BI Asset Management Fondsmaeglerselskab A S Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

BI Asset Management Fondsmaeglerselskab A S grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 46.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,207 shares of the biopharmaceutical company’s stock after acquiring an additional 1,974 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Regeneron Pharmaceuticals were worth $4,791,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of REGN. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $1,012,296,000. Dodge & Cox boosted its holdings in Regeneron Pharmaceuticals by 18.9% during the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after acquiring an additional 724,562 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 528.7% during the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after acquiring an additional 606,612 shares during the last quarter. Invesco Ltd. boosted its holdings in Regeneron Pharmaceuticals by 38.0% during the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after acquiring an additional 408,649 shares during the last quarter. Finally, Caisse de depot et placement du Quebec boosted its holdings in Regeneron Pharmaceuticals by 115.4% during the 3rd quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company’s stock worth $260,051,000 after acquiring an additional 247,780 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $635.45 on Monday. The company has a market cap of $67.18 billion, a PE ratio of 15.48, a price-to-earnings-growth ratio of 1.40 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 52 week low of $485.00 and a 52 week high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm’s 50-day simple moving average is $706.93 and its two-hundred day simple moving average is $742.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the prior year, the firm earned $8.22 earnings per share. The company’s revenue was up 19.0% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a report on Friday, May 1st. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Finally, JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.